Last update 08 May 2025

Institute of Nuclear Energy Research (Taiwan)

Government|1968|Taiwan Province, China|
www.iner.gov.tw

Overview

Tags

Neoplasms
Digestive System Disorders
Respiratory Diseases
Peptide Conjugate Radionuclide
Diagnostic radiopharmaceuticals

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Top 5 Drug TypeCount
Diagnostic radiopharmaceuticals2
Peptide Conjugate Radionuclide2
Top 5 TargetCount
HERs x Integrin1

Related

5
Drugs associated with Institute of Nuclear Energy Research (Taiwan)
Ga68-Dolacga
Target-
Mechanism-
Active Org.
Institute of Nuclear Energy Research (Taiwan)
Originator Org.-
Active Indication
Hepatocellular Carcinoma
Inactive Indication
Hepatitis B
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
68Ga-NOTA-RGD-GE11
Target
HERs x Integrin
Mechanism
HERs modulators [+1]
Active Org.
Institute of Nuclear Energy Research (Taiwan)
Originator Org.
Institute of Nuclear Energy Research (Taiwan)
Active Indication
Lung Cancer
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
188Re-BMEDA-liposome
Target-
Mechanism
Ionising radiation emitters
Active Org.-
Originator Org.
Institute of Nuclear Energy Research (Taiwan)
Active Indication-
Inactive Indication
Solid tumor
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Institute of Nuclear Energy Research (Taiwan)
NCT05007548
/ CompletedPhase 2IIT
An Open-label, Comparative Phase II Clinical Trial to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve Among Scheduled Surgery Operation Patients
NCT02271516
/ TerminatedPhase 1IIT
A Phase I, Open-label, Dose-escalation Study to Determine the Maximum Tolerance Dose (MTD) and to Evaluate the Safety of 188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage.
100 Clinical Results associated with Institute of Nuclear Energy Research (Taiwan)
Login to view more data
0 Patents (Medical) associated with Institute of Nuclear Energy Research (Taiwan)
Login to view more data
100 Deals associated with Institute of Nuclear Energy Research (Taiwan)
Login to view more data
100 Translational Medicine associated with Institute of Nuclear Energy Research (Taiwan)
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
1
Phase 2 Clinical
Other
3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Ga68-Dolacga
Hepatocellular Carcinoma
More
Phase 2
68Ga-NOTA-RGD-GE11
 ( HERs x Integrin )		Lung Cancer
More
Preclinical
188Re-BMEDA-liposome
Solid tumor
More
Discontinued
PDC-949
 ( NET )		Depressive Disorder
More
Pending
111In-BPDA
Neoplasms
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free